To this end, wider use of blood pressure-lowering medications (such as RAS inhibitors) and early combination therapy in those with stage 2 hypertension or beyond (blood pressure ≥ 160/100 mmHg) [42], addressing social determinants of health, and increasing access to newer organ-protective medications such as SGLT2 inhibitors and GLP1-RAs in the public healthcare setting may bring about further reductions in excess mortality risk [10], [37], [43]. This evidence concerns the gene SLC5A2 and hypertensive disorder.